VAKCINA

bemty wrote:

Marius Lăcătuș wrote:aLI neMAmO peER ReVIeW!!!

hteo si da kazes kontrolnu grupu ali dobro, korak po korak.

Sotir wrote:

bemty wrote:

hteo si da kazes kontrolnu grupu ali dobro, korak po korak.

Довољно је да прате колико је вакцинисаних са одређеном вакцином оболело од ког соја.
Пошто знају колико је људи вакцинисано, види се проценат колико је заражено.
Тако може да се види релативна заштита једне вакцине у односу на другу.

kapetanm wrote:Ko je desboj

lalinea wrote:

Sotir wrote:
Довољно је да прате колико је вакцинисаних са одређеном вакцином оболело од ког соја.
Пошто знају колико је људи вакцинисано, види се проценат колико је заражено.
Тако може да се види релативна заштита једне вакцине у односу на другу.

To pod pretpostavkom da su sve grupe jednako izlozene virusu . A nisu. Npr, fajzer se davao prevashodno zdravstvenim radicima (vise izlozena grupa) a sinofarm vise obicnom stanovništvu, i to ne reprezentativnom uzorku populacije, vec onom svesnom opasnosti i vise obazrivom (cim jure da se vakcinisu).
Jbg, ima nesto u toj kontrolnoj grupi, sto kaze bemty.

Desmond Bojčinski wrote:

kapetanm wrote:Ko je desboj

Ja sam onaj što nije iz Erema, rumbi me pomešao.

lalinea wrote:

Sotir wrote:
Довољно је да прате колико је вакцинисаних са одређеном вакцином оболело од ког соја.
Пошто знају колико је људи вакцинисано, види се проценат колико је заражено.
Тако може да се види релативна заштита једне вакцине у односу на другу.

To pod pretpostavkom da su sve grupe jednako izlozene virusu . A nisu. Npr, fajzer se davao prevashodno zdravstvenim radicima (vise izlozena grupa) a sinofarm vise obicnom stanovništvu, i to ne reprezentativnom uzorku populacije, vec onom svesnom opasnosti i vise obazrivom (cim jure da se vakcinisu).
Jbg, ima nesto u toj kontrolnoj grupi, sto kaze bemty.

Talason wrote:zaključak članka je bodi sad će razmišljamo posle

saglasan sam sa stavom

How AstraZeneca’s vaccine was hit by flawed trials, defects and politics — but might still save the world https://t.co/aYQFUfGcFP

— Financial Times (@FT) February 5, 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) is the executive Agency of
the Department of Health and Social Care that acts to protect and promote public health and
patient safety, by ensuring that medicines and medical devices meet appropriate standards of
safety, quality and efficacy.
The MHRA operates the Yellow Card scheme on behalf of the Commission on Human Medicines
(CHM). The scheme collects and monitors information on suspected safety concerns or incidents
involving vaccines, medicines, medical devices, and e-cigarettes.
...

As of 24 January 2021, for the UK, 16,756 Yellow Cards have been reported for the
Pfizer/BioNTech, 6,014 have been reported for the Oxford University/AstraZeneca vaccine, and 50
have been reported where the brand of the vaccine was not specified.
For both vaccines the overall reporting rate is around 3 Yellow Cards per 1,000 doses
administered.
For both vaccines, the overwhelming majority of reports relate to injection-site reactions (sore arm
for example) and generalised symptoms such as ‘flu-like’ illness, headache, chills, fatigue
(tiredness), nausea (feeling sick), fever, dizziness, weakness, aching muscles, and rapid
heartbeat. Generally, these happen shortly after the vaccination and are not associated with more
serious or lasting illness.
These types of reactions reflect the normal immune response triggered by the body to the
vaccines. They are typically seen with most types of vaccine and tend to resolve within a day or
two. The nature of reported suspected side effects is broadly similar across age groups, although,
as was seen in clinical trials and as is usually seen with other vaccines, they may be reported more
frequently in younger adults. 
...
Widespread use of the vaccine now suggests that severe allergic reactions to the Pfizer/BioNTech
vaccine are very rare (less than 1 in 10,000 people receiving this vaccine) and have been reported
at a rate between 1 and 2 cases per 100,000 doses administered. Similar reporting was seen in
the United States with the same vaccine. Anaphylaxis can also be a very rare side effect
associated with most other vaccines.
Following very substantial exposure across the UK population, no other new safety concerns have
been identified from reports received so far. 

British regulators have received extra trial data from AstraZeneca that supports their view that the Covid-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said on Friday.
...
Munir Pirmohamed, chair of the Commission on Human Medicines’ Covid-19 Vaccines Benefit Risk Expert Working Group, said British regulators had noticed the smaller number of under-65s in the data when they approved the vaccine.

“Nevertheless, there was no evidence there, suggesting that those people over 65 were not getting evidence of efficacy,” he said at an MHRA news briefing, asked by Reuters about efficacy of the shot in the elderly.

“Since then we’ve seen more data coming through from AstraZeneca as more people are completing the trial, which highlights again that efficacy in the elderly is seen, and there’s no evidence of lack of efficacy.”

Talason wrote:

Desmond Bojčinski wrote:

Ja sam onaj što nije iz Erema, rumbi me pomešao.

L nisam mogao da odoo
razmisli još malo koji si, on ne greši

rumbeando wrote:

U Čileu za tri dana vakcinisano 556.000 ljudi https://t.co/uNk5luUTu5

— TV N1 Beograd (@N1infoBG) February 6, 2021

The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study due to be published on Monday.
Although none of the more than 2,000 mainly healthy and young patients in the study died or was hospitalised, the findings, which have not yet been peer reviewed, could complicate the race to roll out vaccines as new strains emerge.
In both the human trials and tests on the blood of those vaccinated, the jab showed significantly reduced efficacy against the 501Y.V2 viral variant, which is dominant in South Africa, according to the randomised, double-blind study seen by the Financial Times.
“A two-dose regimen of [the vaccine] did not show protection against mild-moderate Covid-19 due to [the South African variant]”, the study says, adding that efficacy against severe Covid-19, hospitalisations and deaths was not yet determined.
...
There are caveats to the Oxford/AstraZeneca study, as the sample sizes were relatively small. The study, led by South Africa’s University of the Witwatersrand and Oxford university, enrolled 2,026 HIV negative individuals, with a median age of 31. Half the group was given at least one dose of placebo, with the other half receiving at least one dose of vaccine.
...